Ariad Pharmaceuticals (ARIA) 5.38 $ARIA
ARIAD Reports Second Quarter 2014 Financial Results and Development Progress
Business Wire - Wed Aug 06, 6:35AM CDT
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today reported financial results for the second quarter of 2014, including revenue from sales of Iclusig(R) (ponatinib). The Company also provided an update on corporate developments.
Will GW Pharmaceuticals (GWPH) Miss this Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 05, 3:45PM CDT
GW Pharmaceuticals (GWPH) is scheduled to report third-quarter fiscal 2014 results on Aug 6.
Should You Sell Ariad Pharmaceuticals (ARIA) Before Earnings? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Aug 05, 7:48AM CDT
Ariad Pharmaceuticals (ARIA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season. The company looks set to produce a positive earnings surprise and outperform the market.
ARIAD Announces Commercial Agreement for Iclusig (Ponatinib) in Israel
Business Wire - Tue Aug 05, 6:35AM CDT
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) and Medison Pharma Ltd, Israel's leading international marketing group for innovative pharmaceuticals, today announced that ARIAD has granted Medison exclusive rights to commercialize Iclusig(R) (ponatinib) in Israel in patients with Philadelphia-positive (Ph+) leukemias.
The Zacks Analyst Blog Highlights: AbbVie, Shire, ARIAD Pharmaceuticals, ImmunoGen and Durata Therapeutics
PR Newswire - Fri Aug 01, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the AbbVie Inc. (NYSE:ABBV-Free Report), Shire (Nasdaq:SHPG-Free Report), ARIAD Pharmaceuticals, Inc. (Nasdaq:ARIA-Free Report), ImmunoGen, Inc. (Nasdaq:IMGN-Free Report) and Durata Therapeutics, Inc. (Nasdaq
RTX-Free Report).
Biotech Stocks Technical Data -- MannKind, ARIAD Pharma, Galena Biopharma, Geron, and Peregrine Pharma
PR Newswire - Fri Aug 01, 8:00AM CDT
On Thursday, July 31, 2014, the NASDAQ Composite ended at 4,369.77, down 2.09%, the Dow Jones Industrial Average finished the day 1.88% lower at 16,563.30, and the S&P 500 closed at 1,930.67, down 2.00%. The losses were broad based as all the ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 704.37, down 2.03%, and the index has declined 0.02% in the last one month. Investor-Edge has initiated coverage on the following equities: MannKind Corporation (NASDAQ: MNKD), ARIAD Pharmaceuticals Inc. (NASDAQ: ARIA), Galena Biopharma Inc. (NASDAQ: GALE), Geron Corporation(NASDAQ: GERN), and Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM). Free research on these five companies can be accessed at:
3 Eye-Catching Health Care Stocks this Earnings Season - Earnings ESP
Zacks Equity Research - Zacks Investment Research - Thu Jul 31, 10:44AM CDT
These stocks are well positioned in today’s market environment.
3 Biotech Stocks Under $10 in Breakout Territory
at The Street - Wed Jul 30, 5:00AM CDT
These under-$10 biotech stocks are within range of triggering breakout trades.
Storm The Castle: ARIAD Pharmaceuticals (ARIA)
at The Street - Tue Jul 29, 1:35PM CDT
Trade-Ideas LLC identified ARIAD Pharmaceuticals (ARIA) as a "storm the castle" (crossing above the 200-day simple moving average on higher than normal relative volume) candidate
Nasdaq stocks posting largest percentage increases
AP - Thu Jul 24, 5:23PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
Most active Nasdaq-traded stocks
AP - Thu Jul 24, 5:23PM CDT
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:
3 Huge Stocks to Trade (or Not)
at The Street - Thu Jul 24, 2:09PM CDT
Here's how to trade some of the most active stocks on the market today.
Ariad Pharmaceuticals (ARIA) Worth Watching: Stock Gains 15.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 24, 8:25AM CDT
Ariad Pharmaceuticals (ARIA) was a big mover last session, with shares rising over 15% on the day.
'Fast Money' Recap: Facebook and Analysts' Expectations
at The Street - Thu Jul 24, 4:00AM CDT
The trading panel discussed why they like Facebook's earnings and why they'd avoid Cheesecake Factory.
Ariad Pharmaceuticals Rises 15.29% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Wed Jul 23, 4:36PM CDT
Ariad Pharmaceuticals (NASDAQ:ARIA) traded in a range yesterday that spanned from a low of $5.12 to a high of $5.94. Yesterday, the shares gained 15.3%, which took the trading range above the 3-day high of $5.31 on volume of 24.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Ariad Pharmaceuticals Down 13.1% Since SmarTrend Downtrend Call (ARIA)
Comtex SmarTrend(R) - Wed Jul 23, 9:19AM CDT
SmarTrend identified a Downtrend for Ariad Pharmaceuticals (NASDAQ:ARIA) on July 8th, 2014 at $6.07. In approximately 2 weeks, Ariad Pharmaceuticals has returned 13.11% as of today's recent price of $5.27.
Yellen, Icahn Comments Put a Lid on Small-Cap Stocks, May Hurt Larger Market
at The Street - Wed Jul 16, 10:40AM CDT
Recent comments by Fed Chair Janet Yellen and activist investor Carl Icahn have led to selling pressure in small-cap stocks.
ARIAD to Webcast Conference Call on Second Quarter 2014 Financial Results
Business Wire - Wed Jul 16, 6:35AM CDT
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will report its second quarter 2014 financial results on Wednesday, August 6, 2014, before the market opens. Following the announcement, at 8:30 a.m. Eastern Time, company management will host a conference call and webcast discussion of the results and provide a general corporate update.
Ariad Stock's Biggest Risk Is Its Only Hope
Brian Wilson, The Motley Fool - Motley Fool - Tue Jul 15, 4:00PM CDT
Overreliance on its blood cancer drug Iclusig (ponatinib) continues to make Ariad Pharmaceuticals an incredibly risky biotech play, despite the mature company's relatively low market cap of $1.1 billion. After a dramatic FDA recall in 2013 based...
ARIAD Reports Second Quarter 2014 Financial Results and Development Progress
Business Wire - Wed Aug 06, 6:35AM CDT
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today reported financial results for the second quarter of 2014, including revenue from sales of Iclusig(R) (ponatinib). The Company also provided an update on corporate developments.
Will GW Pharmaceuticals (GWPH) Miss this Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 05, 3:45PM CDT
GW Pharmaceuticals (GWPH) is scheduled to report third-quarter fiscal 2014 results on Aug 6.
Should You Sell Ariad Pharmaceuticals (ARIA) Before Earnings? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Aug 05, 7:48AM CDT
Ariad Pharmaceuticals (ARIA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season. The company looks set to produce a positive earnings surprise and outperform the market.
ARIAD Announces Commercial Agreement for Iclusig (Ponatinib) in Israel
Business Wire - Tue Aug 05, 6:35AM CDT
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) and Medison Pharma Ltd, Israel's leading international marketing group for innovative pharmaceuticals, today announced that ARIAD has granted Medison exclusive rights to commercialize Iclusig(R) (ponatinib) in Israel in patients with Philadelphia-positive (Ph+) leukemias.
The Zacks Analyst Blog Highlights: AbbVie, Shire, ARIAD Pharmaceuticals, ImmunoGen and Durata Therapeutics
PR Newswire - Fri Aug 01, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the AbbVie Inc. (NYSE:ABBV-Free Report), Shire (Nasdaq:SHPG-Free Report), ARIAD Pharmaceuticals, Inc. (Nasdaq:ARIA-Free Report), ImmunoGen, Inc. (Nasdaq:IMGN-Free Report) and Durata Therapeutics, Inc. (Nasdaq
RTX-Free Report). Biotech Stocks Technical Data -- MannKind, ARIAD Pharma, Galena Biopharma, Geron, and Peregrine Pharma
PR Newswire - Fri Aug 01, 8:00AM CDT
On Thursday, July 31, 2014, the NASDAQ Composite ended at 4,369.77, down 2.09%, the Dow Jones Industrial Average finished the day 1.88% lower at 16,563.30, and the S&P 500 closed at 1,930.67, down 2.00%. The losses were broad based as all the ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 704.37, down 2.03%, and the index has declined 0.02% in the last one month. Investor-Edge has initiated coverage on the following equities: MannKind Corporation (NASDAQ: MNKD), ARIAD Pharmaceuticals Inc. (NASDAQ: ARIA), Galena Biopharma Inc. (NASDAQ: GALE), Geron Corporation(NASDAQ: GERN), and Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM). Free research on these five companies can be accessed at:
3 Eye-Catching Health Care Stocks this Earnings Season - Earnings ESP
Zacks Equity Research - Zacks Investment Research - Thu Jul 31, 10:44AM CDT
These stocks are well positioned in today’s market environment.
3 Biotech Stocks Under $10 in Breakout Territory
at The Street - Wed Jul 30, 5:00AM CDT
These under-$10 biotech stocks are within range of triggering breakout trades.
Storm The Castle: ARIAD Pharmaceuticals (ARIA)
at The Street - Tue Jul 29, 1:35PM CDT
Trade-Ideas LLC identified ARIAD Pharmaceuticals (ARIA) as a "storm the castle" (crossing above the 200-day simple moving average on higher than normal relative volume) candidate
Nasdaq stocks posting largest percentage increases
AP - Thu Jul 24, 5:23PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
Most active Nasdaq-traded stocks
AP - Thu Jul 24, 5:23PM CDT
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:
3 Huge Stocks to Trade (or Not)
at The Street - Thu Jul 24, 2:09PM CDT
Here's how to trade some of the most active stocks on the market today.
Ariad Pharmaceuticals (ARIA) Worth Watching: Stock Gains 15.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 24, 8:25AM CDT
Ariad Pharmaceuticals (ARIA) was a big mover last session, with shares rising over 15% on the day.
'Fast Money' Recap: Facebook and Analysts' Expectations
at The Street - Thu Jul 24, 4:00AM CDT
The trading panel discussed why they like Facebook's earnings and why they'd avoid Cheesecake Factory.
Ariad Pharmaceuticals Rises 15.29% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Wed Jul 23, 4:36PM CDT
Ariad Pharmaceuticals (NASDAQ:ARIA) traded in a range yesterday that spanned from a low of $5.12 to a high of $5.94. Yesterday, the shares gained 15.3%, which took the trading range above the 3-day high of $5.31 on volume of 24.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Ariad Pharmaceuticals Down 13.1% Since SmarTrend Downtrend Call (ARIA)
Comtex SmarTrend(R) - Wed Jul 23, 9:19AM CDT
SmarTrend identified a Downtrend for Ariad Pharmaceuticals (NASDAQ:ARIA) on July 8th, 2014 at $6.07. In approximately 2 weeks, Ariad Pharmaceuticals has returned 13.11% as of today's recent price of $5.27.
Yellen, Icahn Comments Put a Lid on Small-Cap Stocks, May Hurt Larger Market
at The Street - Wed Jul 16, 10:40AM CDT
Recent comments by Fed Chair Janet Yellen and activist investor Carl Icahn have led to selling pressure in small-cap stocks.
ARIAD to Webcast Conference Call on Second Quarter 2014 Financial Results
Business Wire - Wed Jul 16, 6:35AM CDT
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will report its second quarter 2014 financial results on Wednesday, August 6, 2014, before the market opens. Following the announcement, at 8:30 a.m. Eastern Time, company management will host a conference call and webcast discussion of the results and provide a general corporate update.
Ariad Stock's Biggest Risk Is Its Only Hope
Brian Wilson, The Motley Fool - Motley Fool - Tue Jul 15, 4:00PM CDT
Overreliance on its blood cancer drug Iclusig (ponatinib) continues to make Ariad Pharmaceuticals an incredibly risky biotech play, despite the mature company's relatively low market cap of $1.1 billion. After a dramatic FDA recall in 2013 based...
